[A18-75] Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Last updated 01.02.2019
Commission awarded on 30.10.2018 by the Federal Joint Committee (G-BA).
Digestion, metabolism and hormones
Type 2 diabetes mellitus
Added benefit neither proven for monotherapy nor in combination with other blood-glucose lowering drugs; analyses of the SUSTAIN 6 study additionally presented not meaningfullly interpretable
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.